Professor Rob Stein
Rob Stein has been a Consultant in Medical Oncology at University College London Hospitals since 1997 and is Professor of Breast Oncology at UCL.
After completing an undergraduate degree and PhD in Physiology at the University of Cambridge, he went on to study medicine there. His oncology training was at St George’s Hospital Medical School and at UCLH. Between 1994 and 2002 he was a clinician scientist at the UCL branch of the Ludwig Institute for Cancer Research, working on the development of PI3-kinase inhibitors and on the proteomics of cell signalling.
Professor Stein’s research interests are in the treatment of luminal breast cancer and in the validation of prognostic and predictive biomarkers. He was involved in the early clinical development of aromatase inhibitors, and more recently, in the design and management of several large-scale breast cancer clinical trials with a translational component. He is Chief Investigator of the OPTIMA study of the use of tumour gene-expression biomarker assays to direct chemotherapy decisions for primary breast cancer. He has been a member of the Breast Cancer Now SAB and has acted as an advisor for several NICE appraisals. He is a member of the NCRI Breast Clinical Studies Translational & Imaging sub-group and of the executive committee of the UK Breast Cancer Group.